Zealand Pharma A/S (NASDAQ:ZEAL) has been given an average broker rating score of 1.83 (Buy) from the three brokers that cover the company, Zacks Investment Research reports. One analyst has rated the stock with a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company.
Brokers have set a 1 year consensus price objective of $27.33 for the company and are expecting that the company will post ($0.36) EPS for the current quarter, according to Zacks. Zacks has also assigned Zealand Pharma A/S an industry rank of 108 out of 265 based on the ratings given to its competitors.
Several research firms have issued reports on ZEAL. Morgan Stanley began coverage on Zealand Pharma A/S in a research note on Tuesday, September 5th. They issued an “overweight” rating and a $28.00 target price on the stock. Guggenheim began coverage on Zealand Pharma A/S in a research note on Tuesday, September 5th. They issued a “buy” rating and a $28.00 target price on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $26.00 target price on shares of Zealand Pharma A/S in a research note on Monday. Finally, Goldman Sachs Group, Inc. (The) began coverage on Zealand Pharma A/S in a research note on Wednesday, September 27th. They issued a “buy” rating on the stock.
Zealand Pharma A/S (NASDAQ:ZEAL) opened at 18.54 on Friday. The company has a 50-day moving average of $19.16 and a 200-day moving average of $18.86. The company’s market cap is $570.09 million. Zealand Pharma A/S has a 52 week low of $16.07 and a 52 week high of $20.37.
COPYRIGHT VIOLATION NOTICE: This report was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another website, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The original version of this report can be viewed at https://www.dispatchtribunal.com/2017/10/29/zacks-zealand-pharma-as-zeal-given-27-33-consensus-price-target-by-brokerages.html.
Zealand Pharma A/S Company Profile
Zealand Pharma A/S, a biotech company, engages in the discovery, design, and development of novel peptide-based medicines in Denmark. The company markets Lixisenatide, a once-daily prandial GLP-1 peptide receptor agonist for the treatment of type 2 diabetes under the Adlyxin and Lyxumia names; and Soliqua 100/33/Suliqua, a combination of lixisenatide and insulin glargine, and a GLP-1 receptor agonist for the treatment of type 2 diabetes.
Get a free copy of the Zacks research report on Zealand Pharma A/S (ZEAL)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zealand Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zealand Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.